drugset / Trial / NCT01595958

Cyclosporine A in Cardiac Arrest

NCT01595958

Phase 3 Completed 796 enrolled Hospices Civils de Lyon
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.

Timeline

Start
2010-06
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 2.5 mg/kg Intravenous

Indications